HLS Therapeutics Company Description
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally.
The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels.
In addition, the company holds royalty interest in Takeda’s Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A.
HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 92 |
| CEO | Craig Millian |
Contact Details
Address: 10 Carlson Court Etobicoke, Ontario M9W 6L2 Canada | |
| Phone | 647 495 9000 |
| Website | hlstherapeutics.com |
Stock Details
| Ticker Symbol | HLTRF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA40390B1094 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig Stuart Millian M.B.A. | Chief Executive Officer and Director |
| John Hanna CPA, CGA, M.B.A. | Chief Financial Officer and Non-Independent Director |
| Dr. Jason A. Gross Pharm.D. | Vice President of Scientific Affairs |
| Ryan C. Lennox B.A., J.D. | Senior Vice President of Legal, Human Resources and Compliance and Corporate Secretary |
| Brian T. Walsh | Chief Commercial Officer |
| Dave Mason | Investor Relations Officer |
| David Spence | Vice President and Corporate Controller |